Uwe Gottschalk earned his PhD in Chemistry at the University of Münster and Nottingham, delivering his dissertation on drug targeting with monoclonal antibodies. He worked in different capacities for Bayer Health Care from 1991 to 2004, when he became Group Vice President at Sartorius Stedim Biotech, with a global responsibility for bioseparation-related process technology. In 2014, he joined Lonza Pharma/Biotech to establish and lead the global Research and Technology organization. He has been chief scientific officer at Lonza since 2017. In academia, Dr. Gottschalk is currently senior lecturer at the University of Duisburg-Essen and also lectured at the École Polytechnique Fédérale de Lausanne. Uwe Gottschalk is a valued member of a number of associations connected to the pharmaceutical industries, such as the Society for BioChromatography and Nanoseparations, the Management Pool at the Institute of Marketing, University of St. Gallen and the American Chemical Society. He sits on the editorial advisory boards of Pharmaceutical Bioprocessing, Genetic Engineering News and BioPharm International.